AHA Scientific Sessions 2025

Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.

Representing Richmond at AHA 2025:

• Dr Jörg Täubel, Chief Executive Officer
• Miquel Serna Pascual, PHD Representative

We look forward to connecting with attendees to discuss Richmond’s expertise in:

• Early-phase cardiovascular and cardiometabolic research
• First-in-human and dose-ranging studies
• Novel biomarkers and digital endpoints
• Regulatory engagement and global trial delivery
• Patient-first strategies in complex CV trials

If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com

Learn more: AHA 2025 | American Heart Association's Scientific Sessions

‍

‍